The personalised investment company in biotechnology and health, a member of CataloniaBio & HealthTech, has received authorisation from the CNMV to operate under the European law ECSP 2020/1503. This authorisation will allow Capital Cell to start operating immediately in France, Germany, Italy, Portugal, Belgium and Denmark, as well as opening up the possibility of entering the rest of the European Union markets more easily.

"We firmly believe that the Capital Cell model, which has had a great positive impact on the Spanish biotech startup ecosystem, will be just as valuable in other European ecosystems. We will work hard to build a European-wide platform, and this authorisation validates our proposal and opens the way to exponential growth, both for our company and our positive impact", Daniel Oliver, director of Capital Cell.

Capital Cell's investment ecosystem includes Europe's first equity crowdfunding platform specialising in biomedicine/biotechnology and health. Between 2015 and 2023 Capital Cell has transacted more than 80 million euros for 87 companies and is one of the most active investors in biomedical innovation in Spain.

In 2022 Capital Cell successfully closed 17 rounds with a total of 16 million euros. This year has started with a record first quarter, with €7.5 million. These figures have made Capital Cell one of the largest investors in biotechnology in Spain; now, with the European license to operate and an agreement with a multinational in the health sector, the platform is ready to expand its activity throughout Europe.

The company has also published its market performance data, which has multiplied its value by 3.2 between 2015 and 2022. Capital Cell currently has three rounds open on the platform.

Photo: Daniel Oliver, Capital Cell Director